Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know
Viridian Therapeutics分析師評級的重要見解：您需要知道的內容
In the last three months, 8 analysts have published ratings on Viridian Therapeutics (NASDAQ:VRDN), offering a diverse range of perspectives from bullish to bearish.
在過去的三個月中，有8位分析師公佈了對Viridian Therapeutics（納斯達克股票代碼：VRDN）的評級，提供了從看漲到看跌的不同視角。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.0, a high estimate of $56.00, and a low estimate of $27.00. This current average has increased by 2.66% from the previous average price target of $33.12.
分析師評估的12個月目標股價揭示了進一步的見解，平均目標價爲34.0美元，最高估計爲56.00美元，低估值爲27.00美元。目前的平均價格較之前的平均目標價33.12美元上漲了2.66％。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：仔細觀察
The analysis of recent analyst actions sheds...
對分析師最近行...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。